

THE UNITED STATES PATENT AND TRADEMARK OFFICE

This application of: Llinas-Brunet, M. et al

Appln. No.: 09/368,866 Group Art Unit: 1626
Filed: 08/05/99 Examiner: J. Oswecki
For: Hepatitis C Inhibitor Tri-Peptides
Docket No.: 13/068

RECEIVED

SEP 14 2000

TECH CENTER 1600/2200

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In accordance with the duty of disclosure under 37 C.F.R. § 1.56, Applicants hereby notify the U.S. Patent and Trademark Office of the documents listed herein and on the attached PTO-1449 form and which the Examiner may deem relevant to patentability of the claims of the above-identified application.

The Examiner's attention is directed to copending U.S. Application No. 09/368,670, filed on August 5, 1999, Llinas-Brunet, M. et al. (Attny. Docket No. 13/063-2-C2).

☒ 1.97(b). This Statement is being filed within three months of the filing date of a national application; within three months of the date of entry of the national stage as set forth in 37 C.F.R. §1.491 in an international application; or before the mailing of a first Office Action on the merits, whichever event occurs last.

☐ 1.97(c). This Statement is being filed after the time period specified in 37 C.F.R. §1.97(b), but before the mailing date of either a final action under §1.113 or a notice of allowance under 37 C.F.R. §1.311, whichever occurs first. This Statement is being accompanied by:

☐ A certification as specified in 37 C.F.R. §1.97(e); or

☐ The fee set forth in 37 C.F.R. §1.17(p).

☐ The Assistant Commissioner is hereby authorized to charge payment of the \$240.00 fee set forth in 37 C.F.R. §1.17(p) to Deposit Account No. 02-2955.

TRIPLICATE

INFORMATION DISCLOSURE STATEMENT
U.S. APPLN NO. 09/368,670
ATTNY DOCKET NO. 13/063-2-C2



RECEIVED

SEP 14 2000

TECH CENTER 1600/2800

☐ 1.97(d). This Statement is being filed after the mailing of either a final action under 37 C.F.R. §1.113 or a notice of allowance under 37 C.F.R. §1.311, whichever occurs first, but before payment of the issue fee. This Statement is being accompanied by a certification as specified in 37 C.F.R. §1.97(e), a petition requesting consideration of this Statement, and the petition fee set forth in 37 C.F.R. §1.17(i).

☐ The Assistant Commissioner is hereby authorized to charge payment of the \$130.00 fee set forth in 37 C.F.R. §1.17(p) to Deposit Account No. 02-2955.

☒ The Assistant Commissioner is hereby authorized to charge payment of any additional filing fees required under 37 C.F.R. §1.16 and any patent application processing fees under 37 C.F.R. §1.17, or credit any overpayment of same, to Deposit Account No. 02-2955.

Triplicate copies of this form are enclosed.

Respectfully submitted,

Philip I. Datlow

Philip I. Datlow
Attorney for Applicant(s)
Reg. No. 41,482

Patent Department
Boehringer Ingelheim Corp.
900 Ridgebury Road
P.O. Box 368
Ridgefield, CT. 06877
Tel.: (203) 791-4542


I hereby certify that this correspondence is being deposited with the U.S. Postal Service as first class mail in an envelope addressed to:

Assistant Commissioner for Patents
Washington, DC 20231

on September 8, 2000

By: *Philip I. Datlow*
Philip I. Datlow
Reg. No. 41,482

TRIPLICATE



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In application of: Llinas-Brunet, M. et al

Appln. No.: 09/368,866 Group Art Unit: 1626
Filed: 08/05/99 Examiner: J. Oswecki
For: Hepatitis C Inhibitor Tri-Peptides
Docket No.: 13/068

RECEIVED

SEP 14 2000

TECH CENTER 1600/2300

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In accordance with the duty of disclosure under 37 C.F.R. § 1.56, Applicants hereby notify the U.S. Patent and Trademark Office of the documents listed herein and on the attached PTO-1449 form and which the Examiner may deem relevant to patentability of the claims of the above-identified application.

The Examiner's attention is directed to copending U.S. Application No. 09/368,670, filed on August 5, 1999, Llinas-Brunet, M. et al. (Attny. Docket No. 13/063-2-C2).


☒ 1.97(b). This Statement is being filed within three months of the filing date of a national application; within three months of the date of entry of the national stage as set forth in 37 C.F.R. § 1.491 in an international application; or before the mailing of a first Office Action on the merits, whichever event occurs last.

☐ 1.97(c). This Statement is being filed after the time period specified in 37 C.F.R. § 1.97(b), but before the mailing date of either a final action under § 1.113 or a notice of allowance under 37 C.F.R. § 1.311, whichever occurs first. This Statement is being accompanied by:

☐ A certification as specified in 37 C.F.R. § 1.97(e); or

☐ The fee set forth in 37 C.F.R. § 1.17(p).

☐ The Assistant Commissioner is hereby authorized to charge payment of the \$240.00 fee set forth in 37 C.F.R. § 1.17(p) to Deposit Account No. 02-2955.



RECEIVED

SEP 14 2000

TECH. CENTER 1600/2880

INFORMATION DISCLOSURE STATEMENT
U.S. APPLICATION NO. 09/368,670
ATTN DOCKET NO. 13/063-2-C2

☐ 1.97(d). This Statement is being filed after the mailing of either a final action under 37 C.F.R. §1.113 or a notice of allowance under 37 C.F.R. §1.311, whichever occurs first, but before payment of the issue fee. This Statement is being accompanied by a certification as specified in 37 C.F.R. §1.97(e), a petition requesting consideration of this Statement, and the petition fee set forth in 37 C.F.R. §1.17(i).

☐ The Assistant Commissioner is hereby authorized to charge payment of the \$130.00 fee set forth in 37 C.F.R. §1.17(p) to Deposit Account No. 02-2955.

☒ The Assistant Commissioner is hereby authorized to charge payment of any additional filing fees required under 37 C.F.R. §1.16 and any patent application processing fees under 37 C.F.R. §1.17, or credit any overpayment of same, to Deposit Account No. 02-2955.

Triplicate copies of this form are enclosed.

Respectfully submitted,

Philip I. Datlow
Attorney for Applicant(s)
Reg. No. 41,482

Patent Department
Boehringer Ingelheim Corp.
900 Ridgebury Road
P.O. Box 368
Ridgefield, CT. 06877
Tel.: (203) 791-4542

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as first class mail in an envelope addressed to:

Assistant Commissioner for Patents
Washington, DC 20231

on September 8, 2000

By:
Philip I. Datlow
Reg. No. 41,482